GoAI
Get started
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc.

KYTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$8.42

+$0.29 · +3.57%

Aug 21, 4:00 PM ET

Pre-market

$8.45

+$0.03 · +0.36%

Aug 24, 4:04 AM ET

KYTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

60

Neutral

Sentiment

62

Bullish

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Warner Biddle
Listed since
Feb 9, 2024
Employees
149

Market position

Day range

Current $8.42

52-week range

Current $8.42

Open
$8.24
Previous close
$8.13
Volume
663.61K
0.62× average
Average volume
1.07M
Average daily volume
Market cap
511.9M USD
Beta
1.94
Market reference 1
50-day average
$8.127
+3.61% above average
200-day average
$8.3484
+0.86% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
320.98M USD
P/E (TTM)
-2.86×
P/B (TTM)
3.1×
P/S (TTM)
0×
EV / EBITDA
-2.02×
Earnings yield
-38.77%
Free cash flow yield
-36.95%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-69.45%
Return on assets
-54.90%
Return on invested capital
-64.99%

Financial health

Debt / equity
0.2×
Current ratio
7.75×
Altman Z-score
1.17
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends157%-70%-296%-522%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Operating margin, FY2021: -465.81%Operating margin, FY2022: -418.28%Net margin, FY2021: -465.88%Net margin, FY2022: -411.29%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Operating margin FY2021 -465.81%. Operating margin FY2022 -418.28%. Net margin FY2021 -465.88%. Net margin FY2022 -411.29%.

Income trends

Revenue

7.03M USD+24.20%

Operating income

−169.83M USD-19.09%

Net income

−161.31M USD-26.54%
Income trends across reported periods24.71M USD−46.03M USD−116.77M USD−187.51M USDRevenue, FY2021: 5.66M USDRevenue, FY2022: 7.03M USDOperating income, FY2021: −26.35M USDOperating income, FY2022: −29.38M USDOperating income, FY2023: −62.41M USDOperating income, FY2024: −142.6M USDOperating income, FY2025: −169.83M USDNet income, FY2021: −26.35M USDNet income, FY2022: −28.89M USDNet income, FY2023: −60.37M USDNet income, FY2024: −127.48M USDNet income, FY2025: −161.31M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.66M USD. Revenue FY2022 7.03M USD. Operating income FY2021 −26.35M USD. Operating income FY2022 −29.38M USD. Operating income FY2023 −62.41M USD. Operating income FY2024 −142.6M USD. Operating income FY2025 −169.83M USD. Net income FY2021 −26.35M USD. Net income FY2022 −28.89M USD. Net income FY2023 −60.37M USD. Net income FY2024 −127.48M USD. Net income FY2025 −161.31M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———7.03M USD5.66M USD
Cost of goods sold—2.13M USD1.71M USD——
Gross profit—−2.13M USD−1.71M USD7.03M USD5.66M USD
Research and development133.72M USD112.47M USD48.22M USD28.4M USD25.85M USD
Selling, general, and administrative36.11M USD30.13M USD12.48M USD8.01M USD6.15M USD
Operating expenses169.83M USD140.47M USD60.7M USD36.41M USD32M USD
Interest income9.09M USD15.36M USD2.28M USD565K USD1K USD
Interest expense489K USD142K USD187K USD65K USD3K USD
Depreciation and amortization1.8M USD2.13M USD1.71M USD1.05M USD586K USD
Operating income−169.83M USD−142.6M USD−62.41M USD−29.38M USD−26.35M USD
Net income−161.31M USD−127.48M USD−60.37M USD−28.89M USD−26.35M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
-64.08%
11 comparable reports
Latest EPS result
-0.63
Estimate -0.68 · Beat by 7.12%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.58-0.81-1.03-1.26Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.88, estimate -0.87, surprise -1.15%, Miss. Q2 2025, reported May 13, 2025: actual -1.03, estimate -1.21, surprise +14.88%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.97, estimate -1, surprise +3.00%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.85, estimate -0.97, surprise +12.37%, Beat. Q1 2026, reported Mar 26, 2026: actual -0.8, estimate -0.845, surprise +5.33%, Beat. Q2 2026, reported May 12, 2026: actual -0.66, estimate -0.75, surprise +12.00%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.63, estimate -0.678, surprise +7.12%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.68, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.00

196.91% upside
Past 12 months12-month forecastHigh $25.00Average $25.00Low $25.00

KYTX news

seekingalpha.com

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval

Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients…

Read source
globenewswire.com

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunology

Read source
seekingalpha.com

Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement

Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. Rolling BLA submission for miv-cel in SPS is underway, targeting completion by Q4 2026, supported…

Read source
globenewswire.com

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

EMERYVILLE, Calif., and WALTHAM, Mass.

Read source
247wallst.com

Kyverna Therapeutics Sinks 13%: Here's Why

Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81.

Read source
seekingalpha.com

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a…

Read source

KYTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KYTX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.25M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.59M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
3.79M
Weight
0.06%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.19M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.84M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.28M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
State Street SPDR S&P Kensho New Economies Composite ETF logoState Street SPDR S&P Kensho New Economies Composite ETFKOMP
Market value
2.1M
Weight
0.08%
AUM
2.71B USD
Expense ratio
0.20%
Price / 1D
$69.24+0.92%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.72M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research KYTX

research.disclaimer